ATR + HMA (e.g., ceralasertib + azacitidine) induced cytoreduction and molecular responses in high-risk MDS and low-blast AML, including post-HMA failure, with a 2024 trial reporting a 35% overall response rate (ORR) (Bataller et al., 2024). The gene discussed is ATR; the disease is acute myeloid leukemia.